帕博利珠单抗单药治疗既往经治的转移性三阴性乳腺癌:II期KEYNOTE-086研究A队列
KEYNOTE-086研究A队列纳入170例既往接受过治疗的转移性三阴性乳腺癌女性患者,接受帕博利珠单抗200 mg静脉注射每3周一次,最长2年。总人群客观缓解率为5.3%,PD-L1阳性人群为5.7%,中位无进展生存期2.0个月,中位总生存期9.0个月。帕博利珠单抗单药在部分患者中显示出持久的抗肿瘤活性,安全性可控。
要点
- 总人群客观缓解率为5.3%,PD-L1阳性人群为5.7%。
- 中位无进展生存期2.0个月,6个月无进展生存率为14.9%。
- 中位总生存期9.0个月,6个月总生存率为69.1%。
核心结论
- 帕博利珠单抗单药在部分既往经治的转移性三阴性乳腺癌患者中显示出持久的抗肿瘤活性,且安全性可控。
研究设计与样本
- II期KEYNOTE-086研究A队列,纳入170例经中心确认的转移性三阴性乳腺癌女性患者。
- 患者既往至少接受过1线针对转移性疾病的全身治疗,且在任何疾病阶段接受过蒽环类和紫杉类治疗,并在最近一次治疗后进展。
- 患者接受帕博利珠单抗200 mg静脉注射每3周一次,最长2年。
- 主要终点为总人群和PD-L1阳性人群的客观缓解率及安全性。
主要发现
- 所有入组患者(N=170)均为女性,61.8%为PD-L1阳性肿瘤,43.5%既往接受过≥3线针对转移性疾病的治疗。
- 总人群客观缓解率(95%CI)为5.3%(2.7-9.9),PD-L1阳性人群为5.7%(2.4-12.2)。
- 总人群疾病控制率(95%CI)为7.6%(4.4-12.7),PD-L1阳性人群为9.5%(5.1-16.8)。
- 总人群(范围1.2+-21.5+)和PD-L1阳性人群(范围6.3-21.5+)的中位缓解持续时间均未达到。
- 中位无进展生存期为2.0个月(95%CI 1.9-2.0),6个月无进展生存率为14.9%;中位总生存期为9.0个月(95%CI 7.6-11.2),6个月总生存率为69.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC. PATIENTS AND METHODS: Eligible patients had centrally confirmed mTNBC, ≥1 systemic therapy for metastatic disease, prior treatment with anthracycline and taxane in any disease setting, and progression on or after the most recent therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. Primary end points were objective response rate in the total and PD-L1-positive populations, and safety. Secondary end points included duration of response, disease control rate (percentage of patients with complete or partial response or stable disease for ≥24 weeks), progression-free survival, and overall survival. RESULTS: All enrolled patients (N = 170) were women, 61.8% had PD-L1-positive tumors, and 43.5% had received ≥3 previous lines of therapy for metastatic disease. ORR (95% CI) was 5.3% (2.7-9.9) in the total and 5.7% (2.4-12.2) in the PD-L1-positive populations. Disease control rate (95% CI) was 7.6% (4.4-12.7) and 9.5% (5.1-16.8), respectively. Median duration of response was not reached in the total (range, 1.2+-21.5+) and in the PD-L1-positive (range, 6.3-21.5+) populations. Median PFS was 2.0 months (95% CI, 1.9-2.0), and the 6-month rate was 14.9%. Median OS was 9.0 months (95% CI, 7.6-11.2), and the 6-month rate was 69.1%. Treatment-related adverse events occurred in 103 (60.6%) patients, including 22 (12.9%) with grade 3 or 4 AEs. There were no deaths due to AEs. CONCLUSIONS: Pembrolizumab monotherapy demonstrated durable antitumor activity in a subset of patients with previously treated mTNBC and had a manageable safety profile. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02447003.
引用
- Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019. PMID: 30475950. doi:10.1093/annonc/mdy517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。